Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYT-500
- Development stage
- Unknown
- Lead developer
- EUSA Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**CYT-500** is an investigational prostate-specific membrane antigen-targeted radioimmunoconjugate developed by Cytogen for metastatic androgen-independent prostate cancer, now generally termed metastatic castration-resistant prostate cancer. It comprises the anti-PSMA monoclonal antibody 7E11-C5.3 conjugated through a methoxy-DOTA chelator and radiolabeled with lutetium-177. Following antibody localization to PSMA-expressing prostate-cancer tissue, lutetium-177 delivers beta-particle radiation, with accompanying gamma emissions useful for biodistribution assessment, to produce localized radiation-induced tumor-cell damage. CYT-500 entered a Phase 1 dose-escalation study evaluating safety, tolerability, biodistribution, pharmacokinetics, antibody mass, and lutetium-177 dose.
- Other names
- 177Lu-CYT-500177Lu-meO-DOTA-7E11177Lu-meO-DOTA-7E11-C5.3
02
Targets
PSMA (Prostate-specific membrane antigen)DNA
Beyond the preview
Go deeper on CYT-500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYT-500.